Login
$ASMB
$21.29 +$0.17 (0.8%) Live

Company Executives

Officer Age In this role Joined 2025 pay Source
Jason A. Okazaki Also a director
Chief Executive Officer and President
50 Not stated Not stated $2,482,987
William E. Delaney IV, Ph.D.
Chief Scientific Officer
54 Since 2020
6 years
Not stated $1,264,904
Anuj Gaggar, M.D., Ph.D.
Chief Medical Officer
48 Since 2023
3 years
Not stated $1,246,051
Nicole S. White, Ph.D.
Chief Manufacturing Officer
46 Since 2022
4 years
2020 Not reported
Jeanette M Bjorkquist
PFO and PAO
Title from the Form 4 dated Oct 30, 2026
Not stated Not stated Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
10
serving now
Independent
7 of 10
stated in the proxy
Average tenure
6.0 years
from year joined
CEO also chairs the board
No
William R. Ringo, Jr.
Director Age On board Independent Other public boards 2025 pay Source
Jason A. Okazaki
50 2023
3 years
Not independent None stated Paid as CEO
Anthony E. Altig
70 2012
14 years
Independent None stated $109,465
Tomas Cihlar, Ph.D.
59 2023
3 years
Not independent None stated Not stated
Gina Consylman
54 2020
6 years
Independent None stated $101,965
Robert D. Cook II
67 2024
2 years
Not independent None stated Not stated
Sir Michael Houghton, Ph.D.
75 2021
5 years
Independent None stated Not stated
Lisa R. Johnson-Pratt, M.D.
62 2021
5 years
Independent None stated $94,465
Susan Mahony, Ph.D.
61 2017
9 years
Independent Zymeworks, Inc., Axsome Therapeutics, Inc. $104,465
John G. McHutchison, A.O., M.D.
68 2019
7 years
Independent None stated $94,465
William R. Ringo, Jr. Leaving at the meeting
Not stated Not stated Independent None stated $151,965

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

3 disclosed in the proxy filed Apr 22, 2026
Gilead Sciences, Inc.
$85 million upfront cash payment
October 2023

Option, License and Collaboration Agreement entered into in October 2023 under which the company received an $85 million upfront cash payment and Gilead holds opt-in and license rights to the company's programs.

Gilead Sciences, Inc.
beneficial holder of more than 5% of our capital stock
$15 million
October 2023

Common Stock Purchase Agreement and Investor Rights Agreement entered into in October 2023 under which Gilead made an upfront equity investment by purchasing 1,089,472 shares.

Gilead Sciences, Inc.
beneficial holder of more than 5% of our capital stock
Amount not stated
August 2025

Gilead participated in an August 2025 financing, purchasing 2,295,920 shares of common stock with accompanying Class A and Class B Warrants.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support